Seres therapeutics presents data across its broad microbiome pipeline including new 24-week data from ser-109 phase 3 ecospor iii study in recurrent c. difficile infection at digestive disease week 2021

Cambridge, mass.--(business wire)--seres therapeutics, inc. (nasdaq: mcrb), a leading microbiome therapeutics company, announced the presentation of its final 24-week data from the pivotal phase 3 ecospor iii study evaluating ser-109, an investigational oral microbiome therapy for recurrent c. difficile infection (rcdi). the data presented today in a poster of distinction at digestive disease week® 2021 demonstrated that ser-109 significantly reduced recurrence rates compared to placebo over 24
MCRB Ratings Summary
MCRB Quant Ranking